Consistently, loss and gain of function studies demonstrate that PIAS1 acts in a SUMO E3 ligase-dependent manner to counteract the ability of TGFβ to induce the invasive and aggressive phenotypes of breast cancer cell-derived organoids. Here, PIAS1 is linked to breast carcinoma.